Download PDF
Semin Vasc Med 2001; 01(2): 213-220
DOI: 10.1055/s-2001-18490
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Thrombolytic Therapy in Pulmonary Embolism

Samuel Z. Goldhaber1 , Henri Bounameaux2
  • 1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
  • 2Division of Angiology and Hemostasis, Department of Internal Medicine, University Hospitals of Geneva, Geneva, Switzerland
Further Information

Publication History

Publication Date:
16 November 2001 (online)

    Permissions and Reprints

ABSTRACT

Successfully utilized contemporary pulmonary embolism (PE) thrombolysis reverses right heart failure rapidly and safely. This therapeutic approach may lower mortality from PE and reduce morbidity from chronic pulmonary hypertension. PE thrombolysis remains a debatable indication because large clinical trials using survival as an endpoint have not been carried out. Instead, thrombolysis trials have been undertaken with surrogate endpoints such as reduction in clot burden, reduction in pulmonary arterial pressure, and improvement in right ventricular function.

Currently, the only contemporary thrombolytic regimen for PE that is approved by the Food and Drug Administration is recombinant tissue plasminogen activator, in a dose of 100 mg/2 h. New thrombolytic agents under development for PE include reteplase, saruplase, and recombinant staphylokinase. Future clinical trials will require multicenter collaboration and focus on clinically relevant endpoints such as reduction of mortality and recurrent venous thromboembolism, under particular consideration of the risk of intracranial hemorrhage that ranges between about 1.7% in clinical trials up to approximately 3.0% in a large registry.

KEYWORD

Thrombolytic therapy - pulmonary embolism - venous thromboembolism

REFERENCES

  • 1 Goldhaber S Z, Visani L, De Rosa M, for ICOPER. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER).  Lancet . 1999;  353 1386-1389
    CrossrefPubMedGoogle Scholar
  • 2 Jerjes-Sanchez C, Ramirez-Rivera A, Garcia M de L. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial.  J Thromb Thrombolysis . 1995;  2 227-229
    CrossrefPubMedGoogle Scholar
  • 3 Cannon C P, Goldhaber S Z. Cardiovascular risk stratification of pulmonary embolism in patients.  Am J Cardiol . 1996;  78 1149-1151
    PubMedGoogle Scholar
  • 4 Kasper W, Konstantinides S, Geibel A, Tiode N, Krause T, Just H. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism.  Heart . 1997;  77 346-349
    PubMedGoogle Scholar
  • 5 Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, Johnsson H, Jorfeldt L. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as predictor of mortality.  Am Heart J . 1997;  134 479-487
    CrossrefPubMedGoogle Scholar
  • 6 Goldhaber S Z. A contemporary approach to thrombolytic therapy for pulmonary embolism.  Vascular Medicine . 2000;  5 115-123
    CrossrefPubMedGoogle Scholar
  • 7 Wicki J, Perrier A, Perneger T V, Bounameaux H, Junod A F. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score.  Thromb Haemost . 2000;  84 548-552
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Grifoni S, Olivotto I, Cecchini P. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction.  Circulation . 2000;  101 2817-2822
    CrossrefPubMedGoogle Scholar
  • 9 Konstantinides S, Geibel A, Kasper W, Olschewski M, Blumel L, Just H. Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism.  Circulation . 1998;  97 1946-1951
    PubMedGoogle Scholar
  • 10 Chartier L, Bera J, Delomez M. Free-floating thrombi in the right heart: diagnosis, management, and prognostic indexes in 38 consecutive patients.  Circulation . 1999;  99 2779-2783
    CrossrefPubMedGoogle Scholar
  • 11 Ribeiro A, Lindmarker P, Johnsson H, Juhlin-Dannfelt A, Jorfeldt L. Pulmonary embolism: one-year follow-up with echocardiography Doppler and five-year survival analysis.  Circulation . 1999;  99 1325-1330
    CrossrefPubMedGoogle Scholar
  • 12 Meyer T, Binder L, Hruska N, Luthe H, Buchwald A B. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction.  J Am Coll Cardiol . 2000;  36 1632-1636
    CrossrefPubMedGoogle Scholar
  • 13 Giannitsis E, Muller-Bardorff M, Kurowski V. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism.  Circulation . 2000;  102 211-217
    CrossrefPubMedGoogle Scholar
  • 14 Carson J L, Kelley M A, Duff A. The clinical course of pulmonary embolism.  N Engl J Med . 1992;  326 1240-1245
    CrossrefPubMedGoogle Scholar
  • 15 Kasper W, Konstantinides S, Geibel A. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry.  J Am Coll Cardiol . 1997;  30 1165-1171
    CrossrefPubMedGoogle Scholar
  • 16 Konstantinides S, Geibel A, Olschewski M. Impact of thrombolytic treatment on the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry.  Circulation . 1997;  96 882-888
    CrossrefPubMedGoogle Scholar
  • 17 Simonneau G, Sors H, Charbonnier B. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.  N Engl J Med . 1997;  337 663-669
    CrossrefPubMedGoogle Scholar
  • 18 The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators.  N Engl J Med . 1997;  337 657-662
    CrossrefPubMedGoogle Scholar
  • 19 The Urokinase Pulmonary Embolism Trial. A national cooperative study.  Circulation . 1973;  47(II) 1-108
    PubMedGoogle Scholar
  • 20 Urokinase-Streptokinase Embolism Trial. Phase 2 results. A cooperative study.  JAMA . 1974;  229 1606-1613
    CrossrefPubMedGoogle Scholar
  • 21 Sharma G R K V, Burleson V A, Sasahara A A. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism.  N Engl J Med . 1980;  303 842-845
    PubMedGoogle Scholar
  • 22 Sharma G R K V, Folland E D, McIntyre K M, Sasahara A A. Long-term benefit of thrombolytic therapy in patients with pulmonary embolism.  Vasc Med . 2000;  5 91-95
    CrossrefPubMedGoogle Scholar
  • 23 Dalla-Volta S, Palla A, Santolicandro A. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen Activator Italian Multicenter Study 2.  J Am Coll Cardiol . 1992;  20 520-526
    CrossrefPubMedGoogle Scholar
  • 24 Goldhaber S Z, Haire W D, Feldstein M L. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right ventricular function and pulmonary perfusion.  Lancet . 1993;  341 507-511
    CrossrefPubMedGoogle Scholar
  • 25 Nass N, McConnell M V, Goldhaber S Z, Chyu S, Solomon S D. Recovery of regional right ventricular function after thrombolysis for pulmonary embolism.  Am J Cardiol . 1999;  83 804-806
    CrossrefPubMedGoogle Scholar
  • 26 Parker J A, Drum D E, Feldstein M L, Goldhaber S Z. Lung scan evaluation of thrombolytic therapy for pulmonary embolism.  J Nucl Med . 1995;  36 364-368
    PubMedGoogle Scholar
  • 27 Daniels L B, Parker J A, Patel S R, Grodstein F, Goldhaber S Z. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism.  Am J Cardiol . 1997;  80 184-188
    CrossrefPubMedGoogle Scholar
  • 28 Kanter D S, Mikkola K M, Patel S R, Parker J A, Goldhaber S Z. Thrombolytic therapy for pulmonary embolism.  Frequency of intracranial hemorrhage and associated risk factors. Chest . 1997;  111 1241-1245
    CrossrefPubMedGoogle Scholar
  • 29 Arcasoy S M, Kreit J W. Thrombolytic therapy of pulmonary embolism. A comprehensive review of current evidence.  Chest . 1999;  115 1695-1707
    CrossrefPubMedGoogle Scholar
  • 30 Meyer G, Gisselbrecht M, Diehl J L, Journois D, Sors H. Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism.  Am J Med . 1998;  105 472-477
    CrossrefPubMedGoogle Scholar
  • 30a Hamel E, Pacouset G, Vincentelli D. Thrombolysis of heparin therapy in massive pulmonary embolism with right ventricular dilation. Results from a 158-patient monocenter registry.  Chest . 2001;  120 120-125
    CrossrefPubMedGoogle Scholar
  • 31 Goldhaber S Z, Vaughan D E, Markis J E. Acute pulmonary embolism treated with tissue plasminogen activator.  Lancet . 1986;  2 886-889
    PubMedGoogle Scholar
  • 32 Goldhaber S Z, Kessler C M, Heit J. A randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism.  Lancet . 1988;  2 293-298
    PubMedGoogle Scholar
  • 33 Goldhaber S Z, Kessler C M, Heit J A. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial.  J Am Coll Cardiol . 1992;  24-30
    PubMedGoogle Scholar
  • 34 Goldhaber S Z, Agnelli G, Levine M N, for the Bolus Alteplase Pulmonary Embolism Group. Reduced dose bolus alteplase versus conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial.  Chest . 1994;  106 718-724
    CrossrefPubMedGoogle Scholar
  • 35 Mikkola K M, Patel S R, Parker J A, Grodstein F, Goldhaber S Z. Increasing age is a major risk factor for hemorrhagic complications following pulmonary embolism thrombolysis.  Am Heart J . 1997;  134 69-72
    CrossrefPubMedGoogle Scholar
  • 36 Verstraete M, Miller G AH, Bounameaux H. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism.  Circulation . 1988;  77 353-360
    CrossrefPubMedGoogle Scholar
  • 37 Patel S R, Parker J A, Grodstein F, Goldhaber S Z. Similarity in presentation and response to thrombolysis among women and men with pulmonary embolism.  J Thromb Thrombolysis . 1998;  5 95-100
    CrossrefPubMedGoogle Scholar
  • 38 Mikkola K M, Patel S R, Parker J A, Grodstein F, Goldhaber S Z. Attentuation over 24 hours of the efficacy of pulmonary embolism thrombolysis among cancer patients.  Am Heart J . 1997;  134 603-607
    PubMedGoogle Scholar
  • 39 Meneveau N, Schiele F, Metz D. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up.  J Am Coll Cardiol . 1998;  31 1057-1063
    CrossrefPubMedGoogle Scholar
  • 40 Tebbe U, Graf A, Kamke W. Hemodynamic effects of double bolus reteplase versus alteplase infusion in a massive pulmonary embolism.  Am Heart J . 1999;  138 39-44
    CrossrefPubMedGoogle Scholar
  • 40a Goldhaber S Z. Thrombolysis in pulmonary embolism: A large-scale clinical trial is overdue.  Circulation 2002 In press.
    PubMedGoogle Scholar
  • 41 Kovacs M J, Anderson D, Morrow B, Gray L, Touchie D, Wells P S. Outpatient treatment of pulmonary embolism with dalteparin.  Thromb Haemost . 2000;  83 209-211
    PubMedGoogle Scholar
      >